Breye Therapeutics is a clinical development stage company that developing new therapies within Opthalmology
The lead program is Danegaptide – an oral drug that can both treat Diabetic Retinopathy and prevent disease progression. Danegaptide can stabilize cell-cell junctions in the retinal capillaries, protect from capillary loss, and prevent vascular leakage and edema.
Location: Copenhagen, Denmark
Sound contact: Johan Kördel (Board Director) and Thomas Tan (Board Observer)
Read an interview with Ulrik Mouritzen, CEO and Founder A visionary journey to innovate sight-preserving therapies
Web: www.breye.com
Related news
- Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
- The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health
- Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
- Breye Therapeutics Strengthens Management Team and Board
- A visionary journey to innovate sight-preserving therapies
- Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases